Research reported in the December 14, 2006 edition of the New England Journal of Medicine states that the addition of Avastin (bevacizumab) to chemotherapy for non-squamous cell, non-small-cell lung cancer (NSCLC) increased patient survival by two months, but treatment-related deaths also rose.
The good news is that median survival was 12.3 months in the group that received a Avastin-chemotherapy combination versus 10.3 months for patients randomized to Taxol (paclitaxel) and Paraplatin (carboplatin) alone (P=0.003).
However, the report was not all good news. There were 15 treatment related deaths in the Avastin group versus two in the Taxol/Paraplatin group.
del.icio.us
Digg this
